Target and dose design of 125I seed brachytherapy for treatment of pediatric borderline tumor in head neck region
10.3760/cma.j.cn112271-20211117-00454
- VernacularTitle:125I粒子治疗儿少期头颈部交界瘤的靶区与剂量设计
- Author:
Yiwei ZHONG
1
;
Xiaoming LYU
;
Yan SHI
;
Mingwei HUANG
;
Lei ZHENG
;
Shuming LIU
;
Chuanbin GUO
;
Jianguo ZHANG
Author Information
1. 北京大学口腔医学院·口腔医院口腔颌面外科 国家口腔疾病临床医学研究中心 口腔数字化医疗技术和材料国家工程实验室 口腔数字医学北京市重点实验室，北京 100081
- Keywords:
Brachytherapy;
Head and neck borderline tumor;
Pediatric;
Dosimetry
- From:
Chinese Journal of Radiological Medicine and Protection
2022;42(2):110-114
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To summarize and evaluate the target and dose design of 125I seed brachytherapy treatment plan of pediatric borderline tumor in head neck region. Methods:Eleven patients underwent definitive 125I brachytherapy or combined with surgery in Peking University Hospital of Stomatology from January 2010 to December 2018 were retrospective analyzed. The target region was set by extending the tumor gross region by 0.5 to 1.0 cm. The prescription dose and activity ranged from 80 to 120 Gy and 18.5 MBq, respectively. The treatments were performed according to the plan under general anesthesia. Response and toxic reaction were recorded during follow-up. The preoperative and postoperative dosimetric results were compared; and the local control rate, objective response rate, complete response rate and acute toxic reaction rate were calculated. Results:There was no statistically significant difference between preoperative and postoperative dosimetric results ( P>0.05). The follow-up time ranged from 33 to 131 months, with a median of 48 months. The local control rate, objective response rate, complete response rate and acute toxic reaction rate were 100%, 100%, 71.4% and 81.8%, respectively. Conclusions:Under well-designed target and dose, 125I brachytherapy for treatment of pediatric borderline tumor in head neck region would bring ideal therapeutic and toxic outcomes, and could be regarded as a feasible therapy.
